Coherex Medical, Inc. announced today that it has entered into an exclusive distribution agreement with Biosense Webster Inc. for the Coherex WaveCrest® LAA Occlusion System.
Under terms of the agreement, Coherex will provide exclusive worldwide distribution rights, excluding the U.S., to Biosense Webster for the CE-marked Coherex WaveCrest Device. Biosense Webster, along with its affiliated company, Cordis Corporation, will promote, train, sell and support the WaveCrest device. Coherex Medical will manufacture the Coherex WaveCrest LAA Occlusion System at its facility in Salt Lake City.
“I am pleased to report that Coherex has accomplished three major objectives,” said Mr. Martin. “First, we have completed our WAVECREST I clinical trial. Second, we have successfully attained CE Mark clearance for the WaveCrest LAA Occlusion System. And third, we are partnering with Biosense Webster in a distribution agreement to market and sell our WaveCrest implant in many countries throughout the world. Biosense Webster is a market leader in atrial fibrillation with significant global reach and expertise. I am very excited that Coherex is entering into this distribution agreement with Biosense Webster.”
The company expects to have a controlled product launch in Europe. Coherex plans to conduct additional clinical trials designed to lead to final approval in the USA and Japan.